trending Market Intelligence /marketintelligence/en/news-insights/trending/5cL4qJc3ZNhA2BMnzwcz0w2 content esgSubNav
In This List

Cara Therapeutics starts $80M common stock offering

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Cara Therapeutics starts $80M common stock offering

Cara Therapeutics Inc. started an underwritten public offering of $80 million of its common shares.

The company expects to grant the underwriters an option to buy up to $12 million of additional shares.

Cara plans to use the proceeds to fund its clinical and research development activities, including the completion of the phase 3 program for I.V. CR845 in uremic pruritus, two phase 3 trials of I.V. CR845 in acute pain and a phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.

Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the proposed offering.